Eupraxia OTC Stock Valuation

EPRXF -  USA Stock  

USD 1.29  0.00  0.00%

What is the value of Eupraxia Pharmaceuticals today? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Eupraxia Pharmaceuticals, is its stock price multiplied by the total number of shares outstanding, calculating Eupraxia Pharmaceuticals' enterprise value requires a different approach. It uses Eupraxia Pharmaceuticals' balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Eupraxia Pharmaceuticals shows a prevailing Real Value of $1.54 per share. The current price of the firm is $1.29. Today, the firm appears to be undervalued. Our model computes the value of Eupraxia Pharmaceuticals from reviewing the firm fundamentals such as Shares Outstanding of 14.24 M, price to book of 0.78 X, and Shares Owned by Institutions of 24.98 % as well as analyzing its technical indicators and Probability Of Bankruptcy. In general, we advise purchasing undervalued instruments and exiting overvalued instruments since, at some point, asset prices and their ongoing real values will submerge.
  
Refresh
Eupraxia Pharmaceuticals Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Eupraxia Pharmaceuticals's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Undervalued
Today 1.29
Share
Please note that Eupraxia Pharmaceuticals' price fluctuation is dangerous at this time. Calculation of the real value of Eupraxia Pharmaceuticals is based on 3 months time horizon. Increasing Eupraxia Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Eupraxia Pharmaceuticals is useful when determining the fair value of the Eupraxia otc stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Eupraxia Pharmaceuticals. Since Eupraxia Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Eupraxia OTC Stock. However, Eupraxia Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
1.54
Real Value
7.12
Upside
Estimating the potential upside or downside of Eupraxia Pharmaceuticals helps investors to forecast how Eupraxia otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eupraxia Pharmaceuticals more accurately as focusing exclusively on Eupraxia Pharmaceuticals' fundamentals will not take into account other important factors:
Hype
Prediction
LowEstimated ValueHigh
0.061.296.87
Details

Eupraxia Pharmaceuticals Total Value Analysis

Eupraxia Pharmaceuticals is currently anticipated to have takeover price of 11.58 M with market capitalization of 18.37 M, debt of 9.56 M, and cash on hands of 29.9 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Eupraxia Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company
  Takeover PriceMarket CapDebt ObligationsCash
11.58 M18.37 M9.56 M29.9 M

Eupraxia Pharmaceuticals Asset Utilization

One of the ways to look at asset utilization of Eupraxia is to check how much profit was generated for every dollar of assets it reports. Eupraxia Pharmaceuticals shows a negative utilization of assets of -69.62 percent, losing $0.7 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Eupraxia Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.

Eupraxia Pharmaceuticals Ownership Allocation (%)

The market capitalization of Eupraxia Pharmaceuticals is $18.37 Million. Eupraxia Pharmaceuticals shows significant amount of outstanding shares owned by insiders and institutional investors .Since such a large part of the company is not owned by regular investors, we recommend to check if there were significant buying or selling the Eupraxia Pharmaceuticals stock in recent months. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
 Ownership % 
      Values 

Eupraxia Pharmaceuticals Profitability Analysis

Net Loss for the year was (22.99 M).
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Eupraxia Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Eupraxia Pharmaceuticals and how it compares across the competition.

About Eupraxia Pharmaceuticals Valuation

The equity valuation mechanism determines the current worth of Eupraxia Pharmaceuticals on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Eupraxia Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Eupraxia Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Eupraxia Pharmaceuticals's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Eupraxia Pharmaceuticals's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Eupraxia Pharmaceuticals. We calculate exposure to Eupraxia Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Eupraxia Pharmaceuticals's related companies.
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada. Eupraxia Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 19 people.

Eupraxia Pharmaceuticals Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Eupraxia Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio13.38
Enterprise Value To Ebitda-0.64
Continue to Investing Opportunities. Note that the Eupraxia Pharmaceuticals information on this page should be used as a complementary analysis to other Eupraxia Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Complementary Tools for Eupraxia OTC Stock analysis

When running Eupraxia Pharmaceuticals price analysis, check to measure Eupraxia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eupraxia Pharmaceuticals is operating at the current time. Most of Eupraxia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eupraxia Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Eupraxia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eupraxia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Is Eupraxia Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eupraxia Pharmaceuticals. If investors know Eupraxia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eupraxia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Eupraxia Pharmaceuticals is measured differently than its book value, which is the value of Eupraxia that is recorded on the company's balance sheet. Investors also form their own opinion of Eupraxia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eupraxia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eupraxia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eupraxia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eupraxia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Eupraxia Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eupraxia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.